On the other hand, Principal Component 2 (PC2) captures the variance in the binding sites of the MLL::AF10 and MLL::AFDN fusion proteins in the AML samples (Fig. 3a, Supplementary Fig. 4b). This evidence concerns the gene MLLT10 and acute myeloid leukemia.